You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Australian regulator approves Endologix's abdominal aortic aneurysm treatment
Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense
Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures
MA Activity The Big Story In Mature Online Video Platform Market
Martina Cheung Backs The Quality Program
The Australian Therapeutic Goods Administration approved Endologix Inc.'s AFX2 Bifurcated Endograft System for inclusion on the Australian register of therapeutic goods.
The regulator has approved the use of AFX2 for the treatment of abdominal aortic aneurysms.
Endologix CEO John McDermott said the approval in Australia will allow the company to start offering the latest version of the anatomical fixation system to physicians and patients starting in 2017.